Hunan Jiudian Pharmaceutical Co Ltd (300705) — Working Capital to Net Assets Ratio
Hunan Jiudian Pharmaceutical Co Ltd (300705) has a Working Capital to Net Assets ratio of 39.8% as of March 2026. Working capital of CN¥1.13 Billion (current assets of CN¥1.55 Billion minus current liabilities of CN¥414.09 Million) is measured against net assets of CN¥2.84 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See operational self-sufficiency of Hunan Jiudian Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hunan Jiudian Pharmaceutical Co Ltd Working Capital to Net Assets (2013–2025)
This chart shows how Hunan Jiudian Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 39.8%, reflecting working capital of CN¥1.13 Billion against net assets of CN¥2.84 Billion CNY. For the complete balance sheet picture, see Hunan Jiudian Pharmaceutical Co Ltd total assets.
Annual Working Capital to Net Assets for Hunan Jiudian Pharmaceutical Co Ltd (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hunan Jiudian Pharmaceutical Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check 300705 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 40.1% | CN¥1.12 Billion | CN¥2.79 Billion | CN¥1.54 Billion | CN¥422.44 Million | ▼ -7.8 pp |
| 2024 | 47.9% | CN¥1.21 Billion | CN¥2.53 Billion | CN¥1.60 Billion | CN¥391.86 Million | ▼ -3.5 pp |
| 2023 | 51.4% | CN¥1.01 Billion | CN¥1.97 Billion | CN¥1.43 Billion | CN¥415.56 Million | ▲ +2.3 pp |
| 2022 | 49.1% | CN¥762.15 Million | CN¥1.55 Billion | CN¥1.21 Billion | CN¥444.34 Million | ▼ -10.0 pp |
| 2021 | 59.1% | CN¥649.90 Million | CN¥1.10 Billion | CN¥1.02 Billion | CN¥370.38 Million | ▲ +20.5 pp |
| 2020 | 38.6% | CN¥322.64 Million | CN¥835.68 Million | CN¥503.60 Million | CN¥180.96 Million | ▲ +5.3 pp |
| 2019 | 33.3% | CN¥253.63 Million | CN¥761.87 Million | CN¥454.18 Million | CN¥200.54 Million | ▼ -9.7 pp |
| 2018 | 43.0% | CN¥308.78 Million | CN¥718.16 Million | CN¥465.91 Million | CN¥157.13 Million | ▼ -23.5 pp |
| 2017 | 66.5% | CN¥438.74 Million | CN¥660.26 Million | CN¥518.69 Million | CN¥79.95 Million | ▲ +16.2 pp |
| 2016 | 50.2% | CN¥162.39 Million | CN¥323.43 Million | CN¥234.61 Million | CN¥72.22 Million | ▲ +3.5 pp |
| 2015 | 46.7% | CN¥118.93 Million | CN¥254.51 Million | CN¥180.94 Million | CN¥62.01 Million | ▲ +4.3 pp |
| 2014 | 42.5% | CN¥89.12 Million | CN¥209.87 Million | CN¥145.91 Million | CN¥56.78 Million | ▲ +1.9 pp |
| 2013 | 40.6% | CN¥71.41 Million | CN¥175.85 Million | CN¥144.56 Million | CN¥73.15 Million | — |